CRISPR THERAPEUTICS AG Operating Expenses
CRISPR THERAPEUTICS AG (CRSP) reported Operating Expenses of $127.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-03
- CRISPR THERAPEUTICS AG operating expenses for the quarter ending 2026-06-30 was $127.45M, a 44.64% decline year-over-year.
- CRISPR THERAPEUTICS AG operating expenses for the quarter ending 2026-03-31 was $131.71M, a 11.78% decline year-over-year.
- CRISPR THERAPEUTICS AG operating expenses for the quarter ending 2025-12-31 was $155.63M, a 55.20% increase year-over-year.
- CRISPR THERAPEUTICS AG operating expenses for the quarter ending 2025-09-30 was $132.95M, a 20.06% increase year-over-year.
- CRISPR THERAPEUTICS AG operating expenses for fiscal 2025 was $668.08M, a 32.59% increase from fiscal 2024.
- CRISPR THERAPEUTICS AG operating expenses for fiscal 2024 was $503.88M, a 15.14% decline from fiscal 2023.
- CRISPR THERAPEUTICS AG operating expenses for fiscal 2023 was $593.74M, a 11.95% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG operating expenses for fiscal 2022 was $674.36M, a 24.55% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $127.45M 10-Q · filed 2026-08-03 | $259.16M 10-Q · filed 2026-08-03 | $414.78M derived: sum of 3 quarters · filed 2026-08-03 | $547.73M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $131.71M 10-Q · filed 2026-05-04 | $287.33M derived: sum of 2 quarters · filed 2026-05-04 | $420.28M derived: sum of 3 quarters · filed 2026-05-04 | $650.50M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $155.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $288.58M derived: sum of 2 quarters · filed 2026-02-12 | $518.79M derived: sum of 3 quarters · filed 2026-08-03 | $668.08M 10-K · filed 2026-02-12 |
| 2025-09-30 | $132.95M 10-Q · filed 2025-11-10 | $363.16M derived: sum of 2 quarters · filed 2026-08-03 | $512.45M 10-Q · filed 2025-11-10 | $612.73M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $230.22M 10-Q · filed 2026-08-03 | $379.50M 10-Q · filed 2026-08-03 | $479.78M derived: sum of 3 quarters · filed 2026-08-03 | $590.52M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $149.29M 10-Q · filed 2026-05-04 | $249.57M derived: sum of 2 quarters · filed 2026-05-04 | $360.30M derived: sum of 3 quarters · filed 2026-05-04 | $512.08M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $100.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $211.01M derived: sum of 2 quarters · filed 2026-02-12 | $362.79M derived: sum of 3 quarters · filed 2026-02-12 | $503.88M 10-K · filed 2026-02-12 |
| 2024-09-30 | $110.73M 10-Q · filed 2025-11-10 | $262.51M derived: sum of 2 quarters · filed 2025-11-10 | $403.60M 10-Q · filed 2025-11-10 | $535.22M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $151.78M 10-Q · filed 2025-08-04 | $292.87M 10-Q · filed 2025-08-04 | $424.49M derived: sum of 3 quarters · filed 2026-02-12 | $556.90M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $141.09M 10-Q · filed 2025-05-06 | $272.71M derived: sum of 2 quarters · filed 2026-02-12 | $405.13M derived: sum of 3 quarters · filed 2026-02-12 | $570.35M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $131.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $264.03M derived: sum of 2 quarters · filed 2026-02-12 | $429.26M derived: sum of 3 quarters · filed 2026-02-12 | $593.74M 10-K · filed 2026-02-12 |
| 2023-09-30 | $132.41M 10-Q · filed 2024-11-05 | $297.63M derived: sum of 2 quarters · filed 2024-11-05 | $462.12M 10-Q · filed 2024-11-05 | $593.67M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $165.22M 10-Q · filed 2024-08-05 | $329.71M 10-Q · filed 2024-08-05 | $461.26M derived: sum of 3 quarters · filed 2025-02-11 | $643.74M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $164.49M 10-Q · filed 2024-05-08 | $296.03M derived: sum of 2 quarters · filed 2025-02-11 | $478.52M derived: sum of 3 quarters · filed 2025-02-11 | $661.93M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $131.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $314.03M derived: sum of 2 quarters · filed 2025-02-11 | $497.45M derived: sum of 3 quarters · filed 2025-02-11 | $674.36M 10-K · filed 2025-02-11 |
| 2022-09-30 | $182.48M 10-Q · filed 2023-11-06 | $365.90M derived: sum of 2 quarters · filed 2023-11-06 | $542.81M 10-Q · filed 2023-11-06 | $701.41M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $183.42M 10-Q · filed 2023-08-07 | $360.33M 10-Q · filed 2023-08-07 | $518.93M derived: sum of 3 quarters · filed 2024-02-21 | $648.60M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $176.91M 10-Q · filed 2023-05-08 | $335.51M derived: sum of 2 quarters · filed 2024-02-21 | $465.18M derived: sum of 3 quarters · filed 2024-02-21 | $603.26M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $158.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $288.27M derived: sum of 2 quarters · filed 2024-02-21 | $426.35M derived: sum of 3 quarters · filed 2024-02-21 | $541.43M 10-K · filed 2024-02-21 |
| 2021-09-30 | $129.67M 10-Q · filed 2022-11-01 | $267.76M derived: sum of 2 quarters · filed 2022-11-01 | $382.84M 10-Q · filed 2022-11-01 | $490.97M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $138.08M 10-Q · filed 2022-08-08 | $253.16M 10-Q · filed 2022-08-08 | $361.30M derived: sum of 3 quarters · filed 2022-08-08 | $453.84M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $115.08M 10-Q · filed 2022-05-09 | $223.21M derived: sum of 2 quarters · filed 2022-05-09 | $315.76M derived: sum of 3 quarters · filed 2022-05-09 | $396.49M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $108.13M 10-K · filed 2021-02-16 | $200.68M derived: sum of 2 quarters · filed 2021-11-03 | $281.41M derived: sum of 3 quarters · filed 2021-11-03 | $355.15M 10-K · filed 2023-02-21 |
| 2020-09-30 | $92.55M 10-Q · filed 2021-11-03 | $173.28M derived: sum of 2 quarters · filed 2021-11-03 | $247.02M 10-Q · filed 2021-11-03 | $313.06M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $80.73M 10-Q · filed 2021-07-29 | $154.48M 10-Q · filed 2021-07-29 | $220.51M derived: sum of 3 quarters · filed 2021-07-29 | $293.27M derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $73.74M 10-Q · filed 2021-04-27 | $139.78M derived: sum of 2 quarters · filed 2021-04-27 | $212.54M derived: sum of 3 quarters · filed 2021-04-27 | $267.84M derived: sum of 4 quarters · filed 2021-04-27 |
| 2019-12-31 | $66.03M 10-K · filed 2021-02-16 | $138.80M derived: sum of 2 quarters · filed 2021-02-16 | $194.10M derived: sum of 3 quarters · filed 2021-02-16 | $242.85M 10-K · filed 2022-02-15 |
| 2019-09-30 | $72.77M 10-K · filed 2021-02-16 | $128.07M derived: sum of 2 quarters · filed 2021-02-16 | $176.82M 10-Q · filed 2020-10-28 | $222.16M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $55.30M 10-K · filed 2021-02-16 | $104.05M 10-Q · filed 2020-07-27 | $149.40M derived: sum of 3 quarters · filed 2021-02-16 | $199.39M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | $48.75M 10-K · filed 2021-02-16 | $94.09M derived: sum of 2 quarters · filed 2021-02-16 | $144.09M derived: sum of 3 quarters · filed 2021-02-16 | $182.46M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | $45.34M 10-K · filed 2020-02-12 | $95.34M derived: sum of 2 quarters · filed 2020-02-12 | $133.71M derived: sum of 3 quarters · filed 2020-02-12 | $162.07M 10-K · filed 2021-02-16 |
| 2018-09-30 | $49.99M 10-K · filed 2020-02-12 | $88.37M derived: sum of 2 quarters · filed 2020-02-12 | $116.72M 10-Q · filed 2019-10-28 | $148.08M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $38.37M 10-K · filed 2020-02-12 | $66.73M 10-Q · filed 2019-07-29 | $98.08M derived: sum of 3 quarters · filed 2020-02-12 | $124.04M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $28.36M 10-K · filed 2020-02-12 | $59.71M derived: sum of 2 quarters · filed 2020-02-12 | $85.67M derived: sum of 3 quarters · filed 2020-02-12 | $110.55M derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | $31.35M 10-K · filed 2019-02-25 | $57.31M derived: sum of 2 quarters · filed 2019-02-25 | $82.20M derived: sum of 3 quarters · filed 2019-02-25 | $105.64M 10-K · filed 2020-02-12 |
| 2017-09-30 | $25.96M 10-K · filed 2019-02-25 | $50.84M derived: sum of 2 quarters · filed 2019-02-25 | $74.29M 10-Q · filed 2018-11-07 | $101.95M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $24.89M 10-K · filed 2019-02-25 | $48.34M 10-Q · filed 2018-08-07 | $75.99M derived: sum of 3 quarters · filed 2019-02-25 | $92.15M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | $23.45M 10-K · filed 2019-02-25 | $51.10M derived: sum of 2 quarters · filed 2019-02-25 | $67.26M derived: sum of 3 quarters · filed 2019-02-25 | $84.61M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $27.65M 10-K · filed 2018-03-08 | $43.81M derived: sum of 2 quarters · filed 2018-03-08 | $61.17M derived: sum of 3 quarters · filed 2018-03-08 | $73.29M 10-K · filed 2019-02-25 |
| 2016-09-30 | $16.16M 10-K · filed 2018-03-08 | $33.51M derived: sum of 2 quarters · filed 2018-03-08 | $45.64M 10-Q · filed 2017-11-08 | $58.05M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $17.35M 10-K · filed 2018-03-08 | $29.48M 10-Q · filed 2017-08-10 | $41.89M derived: sum of 3 quarters · filed 2018-03-08 | $48.10M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $12.13M 10-K · filed 2018-03-08 | $24.54M derived: sum of 2 quarters · filed 2018-03-08 | $30.74M derived: sum of 3 quarters · filed 2018-03-08 | $34.37M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $12.41M 10-K · filed 2017-03-10 | $18.61M derived: sum of 2 quarters · filed 2017-03-10 | $22.24M derived: sum of 3 quarters · filed 2017-03-10 | $25.98M 10-K · filed 2018-03-08 |
| 2015-09-30 | $6.20M 10-K · filed 2017-03-10 | $9.83M derived: sum of 2 quarters · filed 2017-03-10 | $13.56M 10-Q · filed 2016-11-22 | |
| 2015-06-30 | $3.63M 10-K · filed 2017-03-10 | $7.36M derived: sum of 2 quarters · filed 2017-03-10 | ||
| 2015-03-31 | $3.74M 10-K · filed 2017-03-10 | |||
| 2014-12-31 | $6.63M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |